Market-Moving Trends to Watch in H2 2024
In a market defined by unpredictability, volatility, and fast-paced evolution, it can be challenging to determine where it’s heading and what executives should concern themselves with in the second half of 2024 and beyond. Interest in obesity drugs has led to billions of new prescriptions of GLP-1s, like Wegovy and Ozempic (and consequently, an endless cash flow of revenue for pharma companies,) while geopolitical tensions in China and Ukraine have muddied waters for manufacturers.
We’ve combed through thousands of corporate earnings call transcripts, interviews from our expert call library, research documents, and more—all found within AlphaSense—to identify the top market-moving trends to keep an eye on for H2 2024.
In this report, discover: